Autor(es): Baker Britain,Eça Guimarães Luísa,Tomljenovic Lucija,Agmon-Levin Nancy,Shoenfeld Yehuda

Resumo: With the safety of human papilloma virus vaccine (HPVv) being questioned, this article aims to assess the risks and benefits of the commercially available HPVv. Within the last decade, two vaccines (Gardasil and Cervarix) have been put on the market to prevent infection with the most oncogenic HPV subtypes. Both vaccines contain aluminum adjuvants that are meant to cause a hyper stimulated immune response to prevent HPV infection. The purpose of this paper is to consider the safety of these two vaccines based on the data from the U.S. Vaccine Adverse Event Reporting System (VAERS) and case reports. The current HPVv are both effective and generally safe. However, it should be noted that autoimmune side effects have been reported in several studies. Further research should be done to understand the relationship between HPVv and autoimmunity.

Palavras-Chave: Adjuvant; Aluminum; Autoimmune/inflammatory syndrome induced by adjuvants; Autoimmunity; Guillain Barré syndrome; Human papilloma virus; Postural orthostatic tachycardia syndrome; Premature ovarian failure; Vaccines

Imprenta: Expert Opinion on Drug Safety, v. 14, n. 9, p. 1387-1394, 2015

Identificador do objeto digital: 10.1517/14740338.2015.1073710

Descritores: Guillain-Barre Syndrome - Immune response ; Guillain-Barre Syndrome - Autoimmunity ; Guillain-Barre Syndrome - Immune response ; Guillain-Barre Syndrome - Viral infections ; Guillain-Barre Syndrome - Virus ; Guillain-Barre Syndrome - Vaccine

Data de publicação: 2015

INDICADORES

ACESSO